MX2010006089A - Metodos de tratamiento de enfermedad pulmonar obstructiva cronica. - Google Patents

Metodos de tratamiento de enfermedad pulmonar obstructiva cronica.

Info

Publication number
MX2010006089A
MX2010006089A MX2010006089A MX2010006089A MX2010006089A MX 2010006089 A MX2010006089 A MX 2010006089A MX 2010006089 A MX2010006089 A MX 2010006089A MX 2010006089 A MX2010006089 A MX 2010006089A MX 2010006089 A MX2010006089 A MX 2010006089A
Authority
MX
Mexico
Prior art keywords
methods
angiotensin
administering
effective amount
treating copd
Prior art date
Application number
MX2010006089A
Other languages
English (en)
Inventor
Heribert W Staudinger
Irina V Khanskaya
Jonathan Sadeh
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010006089A publication Critical patent/MX2010006089A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se describe un método de tratamiento de enfermedad obstructiva crónica, dicho método comprende administrar una cantidad efectiva de un antagonista de CXCR2 y administrar una cantidad efectiva de por lo menos un fármaco seleccionado del grupo que consiste de: inhibidores de enzima convertidora de angiotensina, antagonistas de receptor de angiotensina II, beta bloqueadores selectivos, y fármacos reguladores de lípidos; ejemplos del antagonista de CXCR2 incluyen: (fórmulas 1.0A y 1 0B). (ver fórmulas).
MX2010006089A 2007-12-04 2008-12-03 Metodos de tratamiento de enfermedad pulmonar obstructiva cronica. MX2010006089A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99219007P 2007-12-04 2007-12-04
PCT/US2008/085327 WO2009073683A2 (en) 2007-12-04 2008-12-03 Methods of treating copd

Publications (1)

Publication Number Publication Date
MX2010006089A true MX2010006089A (es) 2010-09-22

Family

ID=40260855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006089A MX2010006089A (es) 2007-12-04 2008-12-03 Metodos de tratamiento de enfermedad pulmonar obstructiva cronica.

Country Status (5)

Country Link
US (1) US20110009482A1 (es)
EP (1) EP2252327A2 (es)
CA (1) CA2706883A1 (es)
MX (1) MX2010006089A (es)
WO (1) WO2009073683A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103198C2 (en) 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
WO2011088838A1 (en) 2010-01-25 2011-07-28 H. Lundbeck A/S Novel 6,6a,7,8,9,10-hexahydro-4h-4,8,10a-triaza-acephenanthrylene derivatives as dopamine d2 ligands
CA2821985C (en) * 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
BR112014004963A2 (pt) 2011-09-02 2017-03-21 Novartis Ag sal de colina do composto anti-inflamatório ciclobutanodiona substituído
MX362400B (es) * 2012-03-30 2019-01-16 Dae Woong Pharma Composicion farmaceutica que comprende olmesartan medoxomilo y rosuvastatina o su sal.
CN104326926B (zh) * 2014-09-15 2017-06-20 浙江理工大学 一种琥珀酸美托洛尔的新晶型及其制备方法
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
JP6883917B2 (ja) 2016-03-11 2021-06-09 アルデア バイオサイエンシーズ インク． 結晶性関節障害を処置するためのｃｘｃｒ−２阻害剤
IL275839B2 (en) 2018-01-08 2024-02-01 Chemocentryx Inc Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist
GEP20237476B (en) 2018-09-21 2023-03-27 Pfizer N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
JP2022549066A (ja) * 2019-09-26 2022-11-24 ダイメリックス バイオサイエンス ピーティーワイ リミテッド 疾患の処置のための方法および組成物
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519751A (ja) * 2004-01-30 2007-07-19 シェーリング　コーポレイション Ｃｘｃ−ケモカインレセプターリガンドの結晶多形
CA2657051A1 (en) * 2006-07-07 2008-01-10 Schering Corporation 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands

Also Published As

Publication number Publication date
CA2706883A1 (en) 2009-06-11
US20110009482A1 (en) 2011-01-13
EP2252327A2 (en) 2010-11-24
WO2009073683A3 (en) 2009-09-03
WO2009073683A2 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
MX2010006089A (es) Metodos de tratamiento de enfermedad pulmonar obstructiva cronica.
BRPI0508461A (pt) diaminopirimidinas como antagonistas de p2x3 e p2x2/3
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
WO2008060907A3 (en) Pyrrolo-pyridine kinase inhibitors
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
MY144972A (en) Novel amide derivative for inhibiting the growth of cancer cells
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
MX2009006304A (es) Nuevos compuestos de oxadiazol.
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
TW200738632A (en) Cannabinoid receptor modulators
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
WO2008087491A3 (en) Method for treating or preventing symptoms of hormonal variations
MX346186B (es) Inhibidores de proteina cinasas.
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
ME00479B (me) Lijek za profilaksu i tretman arterioskleroze i hipertenzije
MX360150B (es) Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos.
WO2010053861A3 (en) Biologically active amides
DK1480627T3 (da) Fremgangsmåder til mindskelse af angiogenese
WO2008079727A3 (en) Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
MX2011009604A (es) Compuestos 1,1,1-trifluor-2-hidroxipropilo sustituidos por 2,3-diarilo o por heteroarilo.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal